Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for topical infections caused by pathogenic microorganisms, such as bacterial, viral, yeast, and fungal infections, are ineffective and often lead to drug resistance and recurrence, while existing antifungal products cause toxicity and discomfort.
Innovation Solution
Compositions and methods utilizing human-derived Janthinobacterium lividum, its metabolites, or cell lysate, formulated with prebiotics and additional probiotics, are applied topically to inhibit, treat, or prevent pathogenic microorganisms, modulating the skin microbiome and enhancing skin health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antifungal treatments are used, then pathogenic microorganisms are inhibited, but drug resistance and recurrence occur
Solution Approach 1:
The patent uses probiotic bacteria (Lactobacillus, Bifidobacterium, Streptococcus salivarius) and prebiotics as intermediary agents to modulate the skin microbiome and create an unfavorable environment for pathogenic microorganisms, rather than directly killing them with antifungal drugs. This indirect approach prevents the development of drug resistance while effectively treating infections.
Solution Approach 2:
The patent converts the harmful overgrowth of pathogenic microorganisms into a benefit by using probiotics to competitively exclude them and restore microbial balance. The dysbiosis condition is transformed into an opportunity for probiotic colonization that actively suppresses pathogens through resource competition and antimicrobial peptide production.
2Reliability
If conventional antifungal products are used, then infections are treated, but toxicity and discomfort occur
Solution Approach 1:
The patent employs naturally occurring probiotic bacteria and prebiotics that are biodegradable and non-toxic, replacing persistent synthetic antifungal chemicals. These biological agents safely degrade in the environment and do not accumulate toxic residues on the skin or in the body.
3Object-generated harmful factors
If the skin microbiome is not modulated, then pathogenic microorganisms thrive, but microbiome balance is disrupted
Solution Approach 1:
The patent applies probiotics and prebiotics in advance to establish a protective microbial community before pathogenic microorganisms can establish themselves. This preliminary colonization of beneficial bacteria creates competitive exclusion that prevents pathogen attachment and growth, maintaining microbiome stability proactively rather than reactively.
Data Source
AI summary
Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.